Yale doctor wins American Gastroenterological Association’s highest honor
Dr. Loren Laine, Yale gastroenterologist, has won the American Gastroenterological Association’s (AGA) highest honor, the Julius Friedenwald Medal. He will be presented with the honor at the annual Digestive Disease Week conference on June 25 in Washington, D.C.
First Immunotherapy Approved for Gastric Cancer
The US Food and Drug Administration (FDA) today approved pembrolizumab (Keytruda, Merck) for treatment of gastric or gastroesophageal junction cancer. Pembrolizumab becomes the first immunotherapy approved in the United States for gastric cancer. The approval is limited to patients who have had at least two previous lines of chemotherapy for these recurrent locally advanced or metastatic adenocarcinomas that express programmed death receptor-ligand 1 (PD-L1). The PD-L1 expression must be determined by an FDA-approved test and have a combined positive score (CPS) ≥1. Pembrolizumab is also now the first third-line therapy to be approved in this setting.Source: Medscape
New method can assess quality of centers performing colonoscopies
Colonoscopies are now a routine preventive diagnostic test for millions of Americans each year. While rates are low, complications like perforation, bleeding, and anesthesia-related heart failure can occur. Yale School of Medicine researchers have now developed a quality measure that uses follow-up hospital visits to track the variation in colonoscopy quality among outpatient facilities.
Yale School of Medicine, Department of Surgery Welcomes Dr. Hubbard
Please join us in welcoming our newest faculty member, Matthew Hubbard, M.D., M.S., to the Yale School of Medicine Department of Surgery. Dr. Hubbard joined the Section of Gastrointestinal, Bariatrics as an Assistant Professor in 2015.
Hochster Named President Elect of International Society of Gastrointestinal Oncology
The International Society of Gastrointestinal Oncology (ISGIO) has named Howard Hochster, MD, as president elect. Hochster, Professor of Medical Oncology; Associate Director for Clinical Sciences at Yale Cancer Center; and Director of the Gastrointestinal Cancers Program at Smilow Cancer Hospital at Yale-New Haven, will serve a two-year term as president-elect followed by two years as president.
Dr. Johung on Prognosis of Patients With ALK-Rearranged NSCLC and Brain Metastases
Kimberly L. Johung, MD, PhD, assistant professor of Therapeutic Radiology, Gastrointestinal Cancer Program, Yale Cancer Center, discusses a study that examined the prognosis of patients with ALK-rearranged non–small cell lung cancer (NSCLC) and brain metastases.Source: OncLive
Research in the news: Rare-disease research by Yale authors provides broad insights
Research into rare conditions, such as Gaucher disease (GD), can be challenging and often under-recognized. Two new studies by Yale scientists may not only be game-changers for individuals with GD but also offer insights into the study of other diseases, from cancer and Parkinson’s to obesity.
Research explains how we live in harmony with friendly gut bacteria
Stability in the composition of the hundred trillion bacterial cells in the human gastrointestinal tract is crucial to health, but scientists have been perplexed how our microbiota withstands an onslaught of toxins, dietary changes, and immune response to infections or antibiotics with little change.
Yale study identifies potential bacterial drivers of inflammatory bowel disease
Yale University researchers have identified a handful of bacterial culprits that may drive inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis, using patients’ own intestinal immune responses as a guide.
Component of I.V. drips may reduce acute injury to organs, including the heart
Yale researchers have found that the lactate component of a common saline solution used in hospitals may have anti-inflammatory effects that can reduce injury to major organs. The finding has clinical implications for the treatment of pancreatitis, kidney injury, strokes, and even heart attacks. The study is published online in the journal Gastroenterology.
Beta Blockers Not Effective in Preventing Gastroesophageal Complications from Cirrhosis
Beta blockers are not effective in preventing development of varices—veins in the esophagus that can rupture and bleed—as a consequence of cirrhosis, according to a recent study by Yale School of Medicine researchers in the New England Journal of Medicine.
The Yale Vascular Malformations Program (VaMP) identifies a culprit gene mutation implicated in the pathogenesis of "hepatic hemangiomas".
The Yale New Haven Hospital Vascular Malformations Program (VaMP), via a collaborative multidisciplinary effort, has identified somatic mosaic gene mutations (GJA4 encoding connexin 37) implicated in the pathogenesis of so-called “HEPATIC HEMANGIOMAS” in adult patients. This discovery questions the validity of the very term “hemangioma” in this particular anatomic distribution; and renders – for the first time - objective scientific support to the radiographically and clinically suspected notion that these lesions actually represent VENOUS MALFORMATIOMS - an entity with a completely different natural history, hemodynamics, angioarchitectural profile, and ergo therapeutic susceptibility.Source: Cutaneous and hepatic vascular lesions due to a recurrent somatic GJA4 mutation reveal a pathway for vascular malformation